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Identification of factors predicting recurrence of breast cancer is a long-standing goal, ranging 
from classical clinicopathological factors through to immunohistochemical assays of receptor 
levels and, more recently, the expression levels of several genes. A new paper explores new 
expression markers, especially for late recurrence of oestrogen receptor-positive breast 
cancer. 
 
Refers to Rueda, O. M. et al. Dynamics of breast-cancer relapse reveal late-recurring ER-
positive genomic subgroups. Nature. https://doi.org/10.1038/s41586-019-1007-8 (2019) 
 
Breast cancer has been the subject of many studies aimed at the identification of prognostic 
markers and predictors of response to treatment (TABLE 1). Some of this work is several 
decades old, and the early discoveries of the importance of regional lymph node involvement 
and tumour size remain the most powerful pair of prognostic markers4. These markers have 
been combined with tumour grade, patient age, and treatment type to create the Clinical 
Treatment Score (CTS), which has prognostic value both for early1 and late2 recurrence of 
patients with oestrogen receptor (ER)-positive breast cancers. Immunohistochemical assays 
of ER and progesterone receptor (PR)  protein level expression have also proven to be strong 
predictive biomarkers for response to endocrine treatment9. Furthermore, the levels of 
human epidermal growth factor receptor 2 (HER2) positivity inform on the likelihood of 
response to the anti-HER2 antibody trastuzumab and related agents, which have dramatically 
improved the outcomes of this traditionally poor prognostic patient subgroup. Pathological 
grade (or highly positive immunostaining for the proliferation marker Ki-67) is also a strong 
predictor of response to chemotherapy. Accordingly, these four immunohistochemical 
markers (ER, PR, HER2 and Ki-67) have been combined into the IHC4 score, which has shown 
comparable prognostic value to molecular markers in the first five years of follow up after 
diagnosis1,2. 
In the past decades, a range of RNA-based gene expression scores have also been 
developed and validated in breast cancer3, and have been shown to have additional 
  
prognostic value beyond that provided by CTS, especially during the first 5 years after 
diagnosis. However, only a few of these scores — notably the PAM50-based Prosigna risk of 
recurrence (ROR) score, the EndoPredict assay (EPclin), and the Breast Cancer Index (BCI) — 
have been useful in predicting late recurrence after five years of follow-up monitoring in 
patients with ER-positive breast cancer, which provides important information for deciding 
the duration of endocrine treatment3.  
The recurrence rate for ER-positive tumours is virtually constant for up to 20 years 
after diagnosis4. The reasons for this phenomenon are unclear, but probably involve the re-
emergence of metastatic cancer clones that remain hidden both from detection and 
treatment in the early years (0–5 years) after diagnosis. By contrast, ER-negative tumours 
have a different temporal profile for recurrence, with a much higher recurrence rate in the 
first five years after diagnosis, followed by a lower recurrence rate subsequently5.  
The development of improved markers of late recurrence is a priority for women with 
ER-positive breast cancer. These late recurrences are almost certainly, at least partially, 
related to somatic changes in residual tumour cells after adjuvant therapy. Indeed, mutations 
in the ESR1 gene seem to affect response to treatment with aromatase inhibitors and, at least 
in the metastatic setting, seem to be induced by aromatase inhibitor treatment6. Blood-based 
liquid biopsies performed during follow-up monitoring might be a solution for detecting such 
genetic changes, but our current ability to measure small amounts of cell-free tumour DNA 
or circulating tumour cells in patients without prior metastases is very limited. 
The present study by Rueda and colleagues7 focuses on factors that are apparent in 
the primary tumour specimen and builds upon work using current RNA-expression-based 
prognostic models. The investigators adopted a Markov model approach that is more complex 
than current prognostic models and that estimates the risk of breast cancer relapse and 
mortality over time, by estimating the transition rates through four distinct stages: localized 
diagnosis in the breast, locoregional recurrence, distant recurrence, and, finally, death from 
the disease7. By applying their model to 1,980 patients with breast cancer who had available 
molecular data, the investigators identified different relapse patterns across different 
molecular subgroups, including immunohistochemical subtypes, PAM50 subtypes, and eleven 
IntClust subtypes (which were based on patterns of gene expression and copy number 
variation). The value of this more complicated model is unclear, as most patients do not have 
an identifiable progression through all of these stages and, notably, most distant recurrences 
  
are not preceded by a detectable locoregional recurrence. Nevertheless, improved 
characterization of the tumour at diagnosis using molecular signatures is likely to extend the 
prognostic accuracy beyond that of the currently available signatures. Across the 11 IntClust 
subtypes, the authors found that four of these subtypes were associated with late recurrence 
in patients with ER-positive HER2-negative tumours (IntClust1, IntClust2, IntClust6, and 
IntClust9, which comprised 26% of such tumours). However, whether or not patient 
stratification by discrete subtypes is the best way to utilize molecular data is unclear, and a 
discussion of the key genes that characterize these subtypes would have been useful. Even 
when patients were stratified according to the five PAM50 subtypes (normal, luminal A, 
luminal B, basal, and HER2), the difference in relapse between luminal A and luminal B cancers 
is not dichotomous, but rather a continuous variation based largely on the cell cycle 
progression component of the score, or similar variation of an immunohistochemical Ki-67 
measurement. Several other expression-based algorithms for recurrence have been 
published3 and it would have been useful to indicate what advantages the current 
classification has over these.  
Rueda et al.7 focus on prognostic markers for recurrence, but current breast cancer 
classifications also provide insight into the most appropriate treatment for different tumours, 
which will become an even more pressing need beyond predicting prognosis as new 
treatments are developed. Looking at changes in molecular profiles before and after 
presurgical systemic treatment is also likely to provide useful guidance8. 
Although validation of the findings from the study by Rueda et al.7 in a separate cohort 
is needed, work in this important area of molecular classification of tumours is likely to 
continue to provide additional insights into prognosis and, especially, the most effective 
treatment for individual tumours. 
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The present study by Rueda and colleagues … builds upon work using current RNA-expression-
based prognostic models 
molecular classification of tumours is likely to continue to provide additional insights into 
prognosis 
 
Table 1 | Clinicopathological and molecular biomarkers in breast cancer. 
Marker Uses 
Clinicopathological markers 
Nodal involvement Strongest overall prognostic factor for follow-up 
monitoring, both before and after the first 5 years following 
diagnosis 
Tumour size Important prognostic factor for follow-up monitoring, both 
before and after the first 5 years following diagnosis 
Tumour grade Useful in first 5 years following diagnosis; predicts response 
to cytotoxic chemotherapy 
CTS/CTS5 Model that integrates clinical factors for distant recurrence; 
CTS5 is specific for distant recurrence after 5 years following 
diagnosis 
Immunohistochemistry and/or FISH markers 
ER/PR Useful in the first 5 years following diagnosis; predicts 
response to endocrine therapy 
HER2 Predicts response to trastuzumab and related compounds 
  
Ki-67 Similar to grade; useful in first 5 years following diagnosis; 
predicts response to cytotoxic chemotherapy 
IHC4 Model that integrates ER, PR, HER2, and Ki-67 levels 
RNA expression or gene copy number markers 
Oncotype DX  recurrence 
score  
The first widely used molecular test; uses 21 genes;  
developed for ER-positive node-negative patients 
Mammoprint Uses 70 genes and creates high-risk and low-risk groups 
PAM50-based Prosigna risk 
of recurrence score 
For ER-positive early-stage breast cancer; uses 598 genes 
and clinical data  
EndoPredict (EpClin) For ER-positive HER2-negative early-stage breast cancer; 
uses 12 genes and clinical data; useful for follow-up 
monitoring, both before and after the first 5 years following 
diagnosis 
Breast Cancer Index (BCI) For ER-positive HER2-negative early-stage breast cancer; 
useful for follow-up monitoring, both before and after the 
first 5 years following diagnosis  
IntClust Identifies 11 new subtypes with different recurrence 
characteristics 
CTS, Clinical Treatment Score; ER, oestrogen receptor; PR, progesterone receptor. 
 
